Byron C. Hann

University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center

Box 0981, UCSF

San Francisco, CA 94143-0981

United States

SCHOLARLY PAPERS

2

DOWNLOADS

18

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Exploiting KRAS-Driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

Number of pages: 115 Posted: 07 May 2020
University of California, San Francisco (UCSF) - Division of Hematology and Oncology, University of California, San Francisco (UCSF) - Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF) - Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF) - Department of Medicine, University of California, San Francisco (UCSF) - Department of Pathology, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF) - Division of Hematology and Oncology and University of California, San Francisco (UCSF) - Department of Pharmaceutical Chemistry
Downloads 11 (622,341)

Abstract:

Loading...

Pancreatic ductal adenocarcinoma, Lung adenocarcinoma, Iron metabolism, MAPK Pathway

2.

Integrin αvβ8 on T Cells is Responsible for Suppression of Anti-Tumor Immunity in Syngeneic Models and is a Promising Target for Tumor Immunotherapy

Number of pages: 53 Posted: 19 May 2020
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Department of Dermatology, University of California, San Francisco (UCSF) - Department of Dermatology, University of California, San Francisco (UCSF) - Department of Pathology, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, Pfizer, Inc. - Comparative Medicine, Pfizer, Inc. - Oncology Research Unit, Pfizer, Inc. - Oncology Research Unit, Pfizer, Inc. - Oncology Research Unit, Pfizer Centers for Therapeutic Innovation, University of California, San Francisco (UCSF) - Lung Biology Center, Pfizer Centers for Therapeutic Innovation, University of California, San Francisco (UCSF) - Lung Biology Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center and University of California, San Francisco (UCSF) - Lung Biology Center
Downloads 7 (650,097)

Abstract:

Loading...